Specifically, mutations are significantly enriched in the tumor and PNM of ESCC patients than that of GC PNM (P=0.002 and 0.022, respectively, Fisher’s exact test) for the TP53 signaling pathway. This evidence concerns the gene TP53 and neoplasm.